Want to see HSCS full AI Analyst Report?
HSCS Stock Chart & Stats
$2.39
-$0.05(-2.05%)
At close: 4:00 PM EDT
$2.39
-$0.05(-2.05%)
Day’s Range― - ―
52-Week Range$1.63 - $3.93
Previous CloseN/A
Volume8.21K
Average Volume (3M)58.86K
Market Cap
$8.42M
Enterprise Value$8.50
Total Cash (Recent Filing)$3.40B
Total Debt (Recent Filing)$3.87M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Sep 10, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.80
Shares Outstanding3,899,491
10 Day Avg. Volume93,774
30 Day Avg. Volume58,857
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)1185.36
P/FCF Ratio0.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside402.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthening IP PortfolioA Europe-wide patent on ML-based ECG assessment and a portfolio exceeding 45 granted patents creates a durable technical moat for MyoVista. Broad IP coverage supports licensing, clinical trust and partner integration, improving long-term commercial defensibility and barriers to competitor replication.
Merger Can Provide Scale And Cash FlowThe planned combination with an at-scale, revenue-generating mining platform could materially change HeartSciences' funding profile, providing diversified cash flows, access to capital markets and reduced need for continuous equity raises. If closed, it materially improves runway and strategic optionality.
Early Commercial Traction For MyoVistaLaunch of MyoVista Insights plus reported commercial agreements indicates initial product-market fit and a path toward recurring commercial revenue. Durable commercial traction, even if early, supports future adoption, reimbursement discussions, and partnership-driven scale for the healthcare business unit.
Bears Say
Minimal Revenue, Massive LossesExtremely small revenue versus enormous losses shows the healthcare business is far from self-sustaining. Persistent negative gross profit and multi-billion net losses mean operations cannot be supported by current sales, undermining long-term viability without transformative financing or strategic change.
Severe Operating Cash BurnRepeatedly large negative operating and free cash flows indicate ongoing dependence on external capital. This structural cash burn increases refinancing, dilution and creditor risk, constrains investments in commercialization, and makes execution of multi-quarter strategic plans contingent on new funding.
Governance Concentration And Execution Risk From MergerA post-merger structure that yields ~95% ownership to one party and creates non-economic voting classes concentrates control and reduces minority influence. Combined with elevated leverage, this raises execution, governance and minority shareholder risks that can affect strategic alignment and long-term value capture.
Heart Test Laboratories, Inc. News
HSCS FAQ
What was Heart Test Laboratories, Inc.’s price range in the past 12 months?
Heart Test Laboratories, Inc. lowest stock price was $1.63 and its highest was $3.93 in the past 12 months.
What is Heart Test Laboratories, Inc.’s market cap?
Heart Test Laboratories, Inc.’s market cap is $8.42M.
When is Heart Test Laboratories, Inc.’s upcoming earnings report date?
Heart Test Laboratories, Inc.’s upcoming earnings report date is Sep 10, 2026 which is in 41 days.
How were Heart Test Laboratories, Inc.’s earnings last quarter?
Heart Test Laboratories, Inc. released its earnings results on Jul 22, 2026. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.66 by $0.15.
Is Heart Test Laboratories, Inc. overvalued?
According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued.
Does Heart Test Laboratories, Inc. pay dividends?
Heart Test Laboratories, Inc. does not currently pay dividends.
What is Heart Test Laboratories, Inc.’s EPS estimate?
Heart Test Laboratories, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Heart Test Laboratories, Inc. have?
Heart Test Laboratories, Inc. has 3,899,491 shares outstanding.
What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?
Heart Test Laboratories, Inc. reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.66. Following the earnings report the stock price went up 1.626%.
Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?
Currently, no hedge funds are holding shares in HSCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heart Test Laboratories, Inc.
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
HSCS Stock 12 Month Forecast
Average Price Target
$12.00
▲(402.09% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
PAVmed
―
Tenon Medical, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
12.93% Insiders
1.08% Mutual Funds
0.49% Other Institutional Investors
85.05% Public Companies and
Individual Investors